Bond.az White LogoBond.az Black Logo

Macquarie Raises WeRide Price Target on Robotaxi Growth

Macquarie raises WeRide price target to $15.90 on robotaxi growth. Stock at $7.65, market cap $2.56B. Analysts expect continued sales growth.

Sarah Johnson
BySarah Johnson- Senior Editor
|
0

Bond.az - Macquarie raised its price target on WeRide Inc (NASDAQ:WRD) to $15.90 from $15.30 while maintaining an Outperform rating.

First-quarter sales rose 57% year-over-year to Rmb114 million, driven by higher service revenues. Revenue growth over the last twelve months reached nearly 90%, hitting $97.9 million. The robotaxi fleet expanded to 1,300 units with an average of 17 trips per day, up from 15 in Q4 2025.

WeRide maintained a stable gross margin of approximately 35%. Q1 non-GAAP net loss widened 11% to Rmb326 million. Analysts do not anticipate profitability this year but expect continued sales growth. The stock trades at $7.65 with a market cap of $2.56 billion.

Management expects 2,000 unit deliveries of new GXR models by end-2026. Overseas revenue share is expected to rise in 2026 from one-third in 2025.

The suspension of domestic robotaxi license approvals is temporary, and Middle East business will recover. Quarterly growth slowed due to product sales seasonality and the Iran conflict.

In other news, BofA Securities raised its price target to $11.80. WeRide expanded its partnership with Lenovo to deploy 200,000 autonomous vehicles globally starting in 2026. HSBC initiated coverage with a Buy rating and $11.40 target.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...
Macquarie Raises WeRide Price Target on Robotaxi Growth | Bond.az